TELA Bio (TELA) reported a Q4 net loss Thursday of $0.23 per diluted share, compared to a loss of $0.53 a year earlier.
One analyst polled by FactSet expected a loss of $0.24.
Revenue for the quarter ended Dec. 31 was $17.6 million, up from $17 million a year earlier.
Analysts polled by FactSet expected $23.2 million.
For Q1, the company has a revenue outlook of $17 million to $18 million. Four analysts expect $21 million.
The company expects full-year 2025 revenue between $85 million to $88 million. Analysts expect $93.8 million.
Shares fell 24% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.